2023-07-16-世界卫生组织-Immunization_Marshall_Islands_2023_country_profile_20页_393kb

Marshall Islands immunization coverage estimates according to WHO and UNICEF for 2022 revise based on data received by June 26, 2023, with next revision due July 15, 2024. Most vaccine coverage estimates are derived from reported data but were sometimes based on interpolation, surveys, administrative information, or calibrated to previous years, with fluctuations influenced primarily by small birth cohorts. The data reflects coverage for children aged 19-35 months, which may overestimate true coverage for those under 12 months in some instances.

Key Findings by Vaccine:

• BCG: High coverage levels reported consistently, averaging around 85-95% for most years. Administrative data fluctuations occurred but were predominantly recorded inaccuracies.
• DTP1: Coverage remained consistently above 85% for most years, typically reflecting administrative data but sometimes adjusted based on surveys or official estimates.
• DTP3: Similar to DTP1, most years reported high coverage above 70%. However, some years saw significant declines or inconsistencies based on administrative reports or supply issues.
• IPV1: Introduced as a category in 2015, estimates reached around 95% or more in recent years, showing generally positive trends though some years had lower figures and D-/No empirical data noted.
• MCV1/MCV2/MCV1 estimated/RCV1: Immunization coverage for measles/rubella-containing vaccines varied. MCV1 reached about 80-97%, however some years showed large fluctuations or low estimates. Some years had data relying solely on interpolation or calibration from vaccination campaigns.
• HepBB/HepB3: Coverage for birth hepatitis B doses appeared high once calibrated, but HepB3 showed lower rates sometimes linked to programmatic issues (stockout) or inconsistencies later. Other years showed adherence.
• Hib3: Coverage was typically substantial, varying between 25-98%, slightly more variable than some other vaccines.
• PcV3: PcV3 coverage was lower in many years, fluctuating from 12% (in 2014) to 75% (in 2015). Variability included reported stockouts constraining access.
• Pol3: Estimated polio coverage remained high throughout the years, hovering near 80-98%, reflecting successful maintenance against polio interruption concerns.
• RotaC: Rotavirus vaccination coverage accuracy was occasionally questioned, varying from 33% to 64%, relying on both official and sometimes adjusted data.

These estimates rely heavily on international partners and evaluated empirical data, though often limited by local reporting inconsistencies and small population.
COVID-19 pandemic and other global events may have impacted immunization service delivery, though specific localized issues like administrative inaccuracies and stockouts were noted for certain vaccines.